Henry Dohn, MD
Psychiatry · Pensacola, FLNPI 1407857956
Payments from drug & device makers
Across 358 payments — averaging $184.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$45K
- Neurocrine Biosciences, Inc.$16K
- Jazz Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$806
- Axsome Therapeutics, Inc.$454
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$296
- plus $2K from 19 others
What the payments were for
- Consulting fees$5,8489%
- Speaking & faculty fees$48,38873%
- Travel & lodging$5,7379%
- Food & beverage$5,9469%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 139 | $45,137 |
| Neurocrine Biosciences, Inc. | 81 | $16,434 |
| Jazz Pharmaceuticals Inc. | 5 | $1,303 |
| Otsuka America Pharmaceutical, Inc. | 38 | $806 |
| Axsome Therapeutics, Inc. | 15 | $454 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $296 |
| Johnson & Johnson | 4 | $254 |
| Lundbeck LLC | 11 | $214 |
| Sunovion Pharmaceuticals Inc. | 10 | $182 |
| Idorsia Pharmaceuticals US Inc | 5 | $180 |
| Vanda Pharmaceuticals Inc. | 5 | $112 |
| Almatica Pharma LLC | 4 | $84 |
| Neos Therapeutics, LP | 4 | $75 |
| Corium, LLC | 3 | $70 |
| Supernus Pharmaceuticals, Inc. | 2 | $59 |
| Alkermes, Inc. | 3 | $50 |
| Shire North American Group Inc | 3 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 2 | $31 |
| Bausch Health US, LLC | 1 | $26 |
| Tonix Medicines, Inc. | 1 | $24 |
| Neuronetics, Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$42,926
- INGREZZA$14,586
- SUNOSI$1,160
- REXULTI$234
- VIIBRYD$200
- QUVIVIQ$124
- Auvelity$111
- INVEGA SUSTENNA$111
- INVEGA TRINZA$111
How this compares
$65,973 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 64 | $590,135 |
| VraylarCariprazine Hcl | 85 | $141,967 |
| RexultiBrexpiprazole | 28 | $60,565 |
| Lurasidone Hcl | 43 | $17,414 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $14,705 |
| Duloxetine Hcl | 294 | $10,364 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 206 | $8,012 |
| Bupropion XlBupropion Hcl | 171 | $7,027 |
| Buspirone Hcl | 141 | $4,939 |
| Lamotrigine | 200 | $4,307 |
| Modafinil | 12 | $4,146 |
| Clonazepam | 181 | $3,911 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 111 | $3,866 |
| Trazodone Hcl | 201 | $3,810 |
| Aripiprazole | 63 | $3,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $16,434 | $590,13564 claims |
| AbbVieVraylar | $45,137 | $141,96785 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $806 | $60,56528 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $37 | $14,70524 claims |
| Almatica Pharma LLCSertraline Hcl | $84 | $58849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Pensacola
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.